Association of plasma homocysteine level and N5, N10-methylenetetrahydrofolate reductase gene polymorphism with cerebral infarction

Chinese Medical Sciences Journal

Volumn 17, Issue 4, 2002, Pages 231-235

  Yingdong, Zhang ^a   Zhigang, Zhu ^a   Yang, Liu ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cerebral infarction; Homocysteine; N5, N10 methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOSINE; HOMOCYSTEINE; NUCLEIC ACID BASE; THYMINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTERY THROMBOSIS; ARTICLE; BASE PAIRING; BRAIN INFARCTION; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEREDITY; HUMAN; HUMAN TISSUE; MALE; NUCLEIC ACID BASE SUBSTITUTION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; STROKE; ULTRAVIOLET RADIATION;

AGED; CEREBRAL INFARCTION; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POINT MUTATION; POLYMORPHISM, GENETIC;

EID: 0036986848     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
2. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in elderly population. JAMA 1993; 270: 693-698.
3. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
4. Shen ZJ, Wu L. A rapid high performance capillary electrophoretic method for determination of free amino acids in serum. Chin J Med Lab Sci 1998; 21 (3): 151-154.
5. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular diseases: the European Concerted Action Project. JAMA 1997; 227: 1175-1181.
6. Coull BM, Malinow MR, Beamer N, et al. Elevated plasma homocysteine concentration as a possible independent risk factor for stroke. Stroke 1990; 21: 572-576.
7. Caplan LR. Diagnosis and treatment of ischemic stroke. JAMA 1991; 226: 2413-2420.
8. Losealzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98: 5-7.
9. Stampler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
10. Harker LA, Slichter Sj, Scott CR, et al. Homocysteinemia vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-543.
11. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell grown by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373.
12. Zhu HP, Li Z, Li Y. Analysis of genomic structure of human 5, 10-methylenetetrahydrofolate reductase. J Beijing Med Univ 1998; 3(5): 419-421.
13. Goyette P, Frosst P, Rosenblatt DS, et al. Seven novel mutations in methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052-1059.